|By Le Williams | 2 years ago|
Medical technology company Bay Labs, which is positioned at the forefront of applying artificial intelligence (AI) to cardiovascular imaging, today announced its EchoMD AutoEF software product received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the fully automated clip selection and calculation of left ventricular ejection fraction (EF).
As the single most widely used metric of cardiac function, EF is used as the basis for many clinical decisions. The EchoMD AutoEF algorithms eliminate the need to manually select views, choose the best clips, and manipulate them for quantification, an often time-consuming and highly variable process.
Chief scientific officer for MedStar Health Neil J. Weissman said in a statement,“Left ventricular ejection fraction has been a mainstay of echocardiography for the last 50 years. Bay Labs’ use of artificial intelligence for image selection and automated EF measurement will allow clinicians across a wide range of experience to obtain an accurate evaluation of ventricular function and aid in interpretation of the echocardiograms with greater efficiency.”
EchoMD AutoEF automatically examines all the relevant digital video clips of cardiac cycles from a patient’s echocardiography study, rates them according to image quality, and selects the best ones to calculate the EF, the leading measurement of cardiac function from echocardiograms.
Through partnerships with leading cardiology clinical institutions, and unique expertise in the processing of large diagnostic imaging datasets, Bay Labs has created a massive archive of carefully curated studies optimized for deep learning algorithm development.
Notably, EchoMD AutoEF software can be integrated into any DICOM PACS medical imaging environment and provides cardiologists with results as a seamless part of the routine diagnostic workflow.